UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. | Results of Operations and Financial Condition. |
On November 5, 2020, Calithera Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2020. A copy of this press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit |
Description | |
99.1 | Press Release, dated November 5, 2020 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Calithera Biosciences, Inc. | ||||||
Dated: November 5, 2020 | ||||||
By: | /s/ Susan M. Molineaux | |||||
Susan M. Molineaux | ||||||
President and Chief Executive Officer |
Exhibit 99.1
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
Calithera to Provide Corporate Update via Conference Call and Webcast at
2:00 p.m. PT on November 5, 2020
SOUTH SAN FRANCISCO, Calif., November 5, 2020 (GLOBE NEWSWIRE) Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the third quarter ended September 30, 2020.
To date, 2020 has been a significant year for Calithera as weve made remarkable progress to advance our clinical development efforts across our pipeline and work toward reporting our first pivotal trial results with our lead candidate glutaminase inhibitor telaglenastat, while continuing to strengthen our cash position, said Susan Molineaux, PhD, president and chief executive officer of Calithera. We look forward to reporting top-line results from our pivotal CANTATA trial evaluating telaglenastat in renal cell carcinoma in late fourth quarter of 2020 or early first quarter 2021. We also announced recently the initiation of the first clinical trial to evaluate our novel arginase inhibitor in cystic fibrosis, and the initiation of our first clinical trial evaluating telaglenastat in people with non-small cell lung cancer whose tumors have KEAP1 or NRF2 genetic mutations.
Third Quarter 2020 and Other Recent Program Highlights
| Progress continues toward top-line data readout of pivotal Phase 3 CANTATA randomized trial of telaglenastat and cabozantinib in advanced renal cell carcinoma (RCC). The CANTATA trial is a global, randomized, double-blind clinical trial of telaglenastat combined with cabozantinib, in patients with advanced or metastatic RCC who have received one or two prior treatments. The trial enrolled 444 patients at multiple centers globally. The primary endpoint is progression-free survival (PFS). Calithera expects to report top-line efficacy and safety data from the trial in late fourth quarter of 2020 or early first quarter 2021. |
| KEAPSAKE randomized trial evaluating telaglenastat in non-small cell lung cancer (NSCLC) patients with a KEAP1 or NRF2 genetic mutation enrolled first patient in September. Mutations in the KEAP1/NRF2 pathway, which occur in an estimated 20 percent of NSCLC patients, are associated with aggressive tumor growth and poor outcomes for patients. The double-blind KEAPSAKE trial will enroll approximately 120 patients with stage IV non-squamous NSCLC with tumors that have the KEAP1 or NRF2 mutation. Patients will be randomized to receive telaglenastat or placebo, in combination with pembrolizumab, carboplatin and pemetrexed. The study will evaluate the safety and investigator-assessed PFS of telaglenastat plus this standard-of-care chemo-immunotherapy regimen. Calithera anticipates sharing interim data from the KEAPSAKE trial in 2021. |
| ENTRATA Phase 2 study of telaglenastat with everolimus in RCC survival analysis completed. The ENTRATA trial was a randomized, double-blind, trial designed to evaluate the safety and efficacy of telaglenastat in combination with everolimus versus placebo with everolimus in patients with advanced clear cell RCC who have been treated with at least two prior lines of systemic therapy, including at least one prior VEGFR-targeted tyrosine kinase inhibitor. The trial enrolled 69 patients. The primary endpoint was PFS per investigator assessment with a predetermined threshold of p£0.2 one-sided. Top-line results were reported in June 2019. Telaglenastat, when added to everolimus, doubled the median PFS in heavily pretreated patients with advanced RCC to 3.8 months as compared to 1.9 months for everolimus alone, and reduced the risk of disease progression or death by 36% (HR=0.64, p=0.079 one-sided). Although the study was not powered for survival, it was evaluated as a secondary endpoint, and is now mature enough to be reported. Based on the data cutoff of September 30, 2020, the median overall survival is 14.4 months vs. 9.7 months in the telaglenastat and control arms, respectively (HR=0.80, p=0.24 one-sided). |
| Pfizer clinical collaboration investigating the CDK4/6 inhibitor IBRANCE® with telaglenastat expanded to evaluate the combination in pancreatic cancer patients. In July 2019, Calithera initiated a Phase 1/2 trial of the combination of telaglenastat plus Ibrance in patients with solid tumors including |
expansion cohorts in KRAS-mutated colorectal cancer and KRAS-mutated non-small cell lung cancer. In November, Calithera announced the expansion of this collaboration to include an additional cohort of patients with pancreatic ductal adenocarcinoma (PDAC) whose tumors harbor mutations in both KRAS and CDKN2A. |
| CB-280 arginase inhibitor program advanced. In October, Calithera presented a trial in progress poster at the North American Cystic Fibrosis 2020 Virtual Conference. The presentation included preclinical study results which suggest CB-280 significantly improved lung function and reduced Pseudomonas aeruginosa colony-forming units in pre-clinical models. Arginase inhibition with CB-280 resulted in improved central airway resistance in CFTR knockout mice, and decreased lung infection in wild type and DeltaF508-CFTR-expressing mice infected with Pseudomonas aeruginosa. Enrollment in the Ph1b study is ongoing and Calithera expects to share interim data in 2021. In November, Calithera was awarded up to $2.4M from the Cystic Fibrosis Foundation to support clinical development of CB-280. |
| INCB001158 program continued progress. INCB001158, an internally discovered molecule, is being evaluated in multiple clinical trials for the treatment of patients with solid tumors both as a monotherapy, in combination with anti-PD-1 immunotherapy, and in multiple chemotherapy regimens. While Calithera remains committed to and confident in the INCB001158 development program, Calithera decided to opt out of co-development obligations with Incyte in order to focus resources on internal development programs. |
| Preclinical data presented from CB-668 IL4I1 program. CB-668 is an investigational first-in-class, potent, orally administered IL4I1 inhibitor as a novel immuno-oncology approach to cancer. New preclinical data for CB-668 will be presented at the Society for Immunotherapy of Cancer (SITC) Virtual Meeting November 11-14, 2020. |
Selected Third Quarter 2020 Financial Results
Cash, cash equivalents and investments totaled $137.7 million at September 30, 2020.
Research and development expenses were $18.2 million for the three months ended September 30, 2020, compared to $17.2 million for the same period in the prior year. The increase of $1.0 million was due to a $1.9 million increase in the telaglenastat program and a $1.5 million increase in the CB-280 program, partially offset by a $1.0 million decrease in the INCB001158 program and a decrease of $1.4 million in early stage research.
General and administrative expenses were $4.7 million for the three months ended September 30, 2020, compared with $3.9 million for the same period in the prior year. The increase of $0.8 million was primarily related to an increase in higher personnel-related and facility costs.
Interest and other income, net was $0.2 million for the three months ended September 30, 2020, compared to $0.8 million for the same period in the prior year, mainly as a result of lower interest rates.
Net loss for the three months ended September 30, 2020 was $22.7 million, or $0.32 per share.
Conference Call Information
Calithera will host an update conference call today, Thursday, November 5, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 and referring to conference ID 6869011. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at https://ir.calithera.com/investor-overview. The webcast will be recorded and available for replay on Calitheras website for 30 days.
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, anticipate, estimate, intend, poised and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to Calitheras clinical trials, the clinical and commercial potential of its product candidates; the receipt of top-line efficacy and safety data in the CANTATA trial; the timing of enrollment of the randomized trial in NSCLC patients with genetic mutation NRF2/KEAP1 and the presentation of interim data from this trial; the safety and anti-tumor activity of telaglenastat and cabozantinib, telaglenastat in combination with everolimus, and telaglenastat plus Ibrance; the development of INCB001158 by Calithera and Incyte; and the timing that CB-280 will enter clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calitheras stock price. Additional information concerning these and other risk factors affecting Calitheras business can be found in Calitheras periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Inc.
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Operating expenses: |
||||||||||||||||
Research and development |
$ | 18,157 | $ | 17,221 | $ | 53,938 | $ | 58,388 | ||||||||
General and administrative |
4,744 | 3,906 | 14,786 | 12,054 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
22,901 | 21,127 | 68,724 | 70,442 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss from operations |
(22,901 | ) | (21,127 | ) | (68,724 | ) | (70,442 | ) | ||||||||
Interest and other income, net |
167 | 834 | 1,153 | 2,310 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ | (22,734 | ) | $ | (20,293 | ) | $ | (67,571 | ) | $ | (68,132 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Net loss per share, basic and diluted |
$ | (0.32 | ) | $ | (0.38 | ) | $ | (0.99 | ) | $ | (1.52 | ) | ||||
|
|
|
|
|
|
|
|
|||||||||
Weighted-average common shares used to compute net loss per share, basic and diluted |
70,559 | 53,775 | 68,219 | 44,703 | ||||||||||||
|
|
|
|
|
|
|
|
Calithera Biosciences, Inc.
Selected Consolidated Balance Sheet Financial Data
(in thousands)
(unaudited)
September 30, | December 31, | |||||||
2020 | 2019 | |||||||
Balance Sheet Data: |
||||||||
Cash, cash equivalents and investments |
$ | 137,749 | $ | 157,361 | ||||
Working capital |
120,235 | 140,172 | ||||||
Total assets |
147,708 | 168,768 | ||||||
Total liabilities |
25,112 | 26,342 | ||||||
Accumulated deficit |
(353,672 | ) | (286,101 | ) | ||||
Total stockholders equity |
122,596 | 142,426 |
CONTACTS:
Investor Relations
Jennifer McNealey
Calithera
ir@Calithera.com
650-870-1071
Media
Michele Parisi
Sam Brown, Inc.
micheleparisi@sambrown.com
925-864-5028
Document and Entity Information |
Nov. 05, 2020 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001496671 |
Document Type | 8-K |
Document Period End Date | Nov. 05, 2020 |
Entity Registrant Name | Calithera Biosciences, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36644 |
Entity Tax Identification Number | 27-2366329 |
Entity Address, Address Line One | 343 Oyster Point Blvd. |
Entity Address, Address Line Two | Suite 200 |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | (650) |
Local Phone Number | 870-1000 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, 0.0001 par value |
Trading Symbol | CALA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
&UL4$L! A0#
M% @ IX%E42S+HVQ3! [A !@ ("!#0@ 'AL+W=O
M
4]PJU34'\.MCOYK3U5J&I<;Y_
MK-$[A7LZ2/@F__-K91Q:\?O<>9_0LED,'/5+O]'=G+.:]]?W\UK"LM0 -Q]O
M@J=9"PG11!P2=:P[C&[Z+:):IVD,7/\4-(X)&_/%8L6R^Y?2EMF2Y); K;;"
M*X*:(%PAB,1Q5@%V2S1FV6'C1:#K=H\!]3V/:$!CRF8?U7I<4#^R)=J4V1+.
M%29X6403D,O4D"A^DH= \CO3W)U$6@6:.L6I#E'
MW.CM)*?94!=-CZ2([8IQIX20X[;P1OAX[/%[HO3(9R R@^%5D7I;R =0F+>KAO
MPQ?@!\Q)#JFI4M\ZK<,T")MX)[1P+9T^P"_TN 381&18DRT0FC9PG5(:TT$;
M=(X$H!C==9'$322(MI%PYHN!R:_UL;]CX7()XBI@\!'$5IAD>])HEX5LP&30
M7-_ YE!D4#'M%<"0C(M"3H_!R^8>TXMQDPENC@>XV*--R;JV.W>E3OG0T1:X
MTC;3)U>6"=-(P=E7$*@_P).18!V@03[7$!*6I\6!NDOBS,/&D2*, 2!;\%]"
M+PA, 1:B O)8@)$P+\ &W7BR8B $A,P Z'ZY,LLD)XM()+P<&('8*